	C 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	56.08	80.11	85.27	85.21	80.01	57.54	55.71	55.03	69.69	77.25	91.18	63.20	79.49	82.56	85.74
Cost of Operating Revenue	39.14	60.45	59.38	61.75	54.10	38.33	45.82	45.94	53.47	54.72	77.97	64.03	60.84	58.71	52.61
Gross Profit	16.93	19.66	25.89	23.46	25.91	19.21	9.89	9.09	16.22	22.53	13.21	-0.83	18.64	23.85	33.13
Gross Margin	30.2	24.5	30.4	27.5	32.4	33.4	17.8	16.5	23.3	29.2	14.5	-1.3	23.5	28.9	38.6
Total Operating Expenses	46.27	70.42	77.58	79.46	70.09	54.17	71.05	69.89	78.90	83.81	112.56	96.61	78.04	79.22	80.27
Operating Profit	9.81	9.69	7.68	5.76	9.92	3.37	-15.33	-14.86	-9.22	-6.57	-21.38	-33.40	1.44	3.34	5.47
Operating Margin	17.5	12.1	9.0	6.8	12.4	5.9	-27.5	-27.0	-13.2	-8.5	-23.4	-52.8	1.8	4.0	6.4
Financing Income/(Expense) - Net	-0.66	-0.11	-0.12	-0.44	-0.79	-1.01	-2.44	-2.96	-3.35	-2.93	-2.78	-2.13	-0.61	-0.65	-0.84
Profit before Taxes	9.17	9.58	7.57	10.35	10.82	2.48	-17.53	-14.95	-13.51	-8.99	-23.90	-38.38	-19.57	-9.79	24.58
Income Taxes	0.33	2.44	0.33	0.88	0.19	0.82	-3.72	-0.14	1.74	10.38	-4.59	-7.32	0.03	0.18	-
Profit after Tax	8.84	7.14	7.24	9.47	10.63	1.67	-13.81	-14.81	-24.38	-19.38	-11.29	-20.90	-19.59	-9.97	24.58
PAT Margin	15.8	8.9	8.5	11.1	13.3	2.9	-24.8	-26.9	-35.0	-25.1	-12.4	-33.1	-24.6	-12.1	28.7
EPS - Basic - ex Extraordinary Items	4.51	3.65	3.70	4.83	5.43	0.85	-7.05	-7.56	-7.16	-7.77	-4.53	-8.38	-7.65	-3.72	8.35
EPS - Diluted - ex Extraordinary Items	4.51	3.65	3.70	4.83	5.43	0.85	-7.05	-7.56	-7.16	-7.77	-4.53	-8.38	-7.65	-3.72	8.35
EBIT	9.81	9.69	7.68	5.76	9.92	3.37	-15.33	-14.86	-9.22	-6.57	-21.38	-33.40	1.44	3.34	5.47
EBITDA	10.46	10.50	8.52	6.86	11.08	5.04	-8.89	-8.36	-2.57	0.58	-14.03	-26.38	3.22	4.94	7.06
EBITDA Margin	18.7	13.1	10.0	8.1	13.9	8.8	-16.0	-15.2	-3.7	0.7	-15.4	-41.7	4.0	6.0	8.2

Balance Sheet

Abridged

Understanding Balance Sheet

Brooks Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	41.54	65.94	54.70	54.78	28.28	21.87	30.69	31.74	37.92	47.80	61.18	27.61	31.05	33.88	37.42
Long-Term Investments	0.02	0.02	0.02	0.02	2.49	2.30	2.06	2.10	1.65	1.35	0.28	64.19	43.05	73.65	92.55
Property Plant & Equipment - Net	56.01	56.01	57.31	68.55	109.92	125.31	124.53	117.17	112.85	107.70	124.49	14.81	13.60	13.97	15.71
Total Non-Current Assets	65.22	65.72	77.77	80.76	126.05	142.26	141.97	136.14	119.95	114.28	134.73	81.99	59.40	89.82	110.76
Total Assets	106.76	131.66	132.47	135.55	154.34	164.13	172.67	167.88	157.86	162.08	195.91	109.60	90.45	123.69	148.17
Total Current Liabilities	13.79	24.32	17.97	22.14	26.72	24.26	40.48	47.39	45.80	63.71	48.88	33.02	23.05	22.84	21.81
Long Term Debt	-	-	-	-	0.34	10.73	16.63	13.86	11.93	14.44	10.14	0.60	0.36	1.37	2.10
Total Non-Current Liabilities	1.71	1.94	2.20	1.99	1.10	11.59	17.71	15.34	13.65	19.21	12.71	2.62	1.81	2.75	3.70
Total Liabilities	15.50	26.25	20.18	24.13	27.83	35.85	58.20	62.73	59.45	82.93	61.59	35.64	24.86	25.59	25.52
Total Shareholders' Equity	91.26	105.41	112.29	111.42	126.51	128.28	114.47	105.15	98.42	79.15	63.05	73.95	65.59	98.10	122.66
Minority Interest	-	-	-	-	-	-	-	-	-	-	71.27	-	-	-	-
Total Equity	91.26	105.41	112.29	111.42	126.51	128.28	114.47	105.15	98.42	79.15	134.32	73.95	65.59	98.10	122.66
Total Liabilities & Equity	106.76	131.66	132.47	135.55	154.34	164.13	172.67	167.88	157.86	162.08	195.91	109.60	90.45	123.69	148.17

Cash Flow

Abridged

Understanding Cash Flow Statement

Brooks Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	10.98	8.03	7.76	8.44	7.26	4.12	-8.36	-6.16	-5.02	-5.75	-16.13	-27.97	2.70	4.39	6.81
Working Capital - Increase/(Decrease)	-10.90	-2.64	3.94	-3.98	2.15	5.55	2.31	1.22	-7.62	7.37	-24.31	11.40	-13.07	-2.52	1.78
Net CF from Operating Activities	0.08	5.39	11.70	4.45	9.41	9.68	-6.05	-4.94	-12.64	1.62	-40.45	-16.58	-10.38	1.87	8.59
Capital Expenditures - Net	22.97	0.98	1.98	11.26	35.91	17.07	5.65	-0.66	2.15	5.61	20.31	0.47	0.44	0.91	3.23
Net CF from Investing Activities	-41.92	-1.32	-5.88	-3.44	-14.85	-16.91	-5.27	1.01	-2.47	-5.30	-25.00	0.40	0.08	-45.21	-2.98
Stock - Issuance/(Retirement) - Net	63.00	-	-	-	-	-	-	5.55	17.55	-	-	-	11.27	42.50	-
Debt - LT & ST - Issuance/(Retirement) - Total	-0.90	-	-	0.37	5.11	8.02	14.39	3.28	-4.55	4.17	-7.25	-4.03	-0.87	0.76	0.93
Net Cash Flow from Financing Activities	60.61	0.16	0.29	-0.07	4.32	7.01	11.82	5.78	13.00	4.17	67.17	13.60	10.40	43.26	0.93
Free Cash Flow to Equity	-23.79	4.41	9.72	-6.43	-21.39	0.63	2.69	-1.00	-19.34	0.18	-68.00	-21.08	-11.68	1.71	6.30
Free Operating CF net dividend	-22.89	3.36	9.71	-15.55	-26.50	-7.95	-11.78	-5.81	-15.22	-4.00	-63.66	-17.04	-10.81	0.95	5.09
Free Operating CF	-22.89	3.36	9.71	-15.55	-26.50	-7.95	-11.78	-5.81	-15.22	-4.00	-63.66	-17.04	-10.81	0.95	5.09

Business Segment Analysis

FY End:

Mar 25

Brooks Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical (100.0%)₹ 0.92 Cr

Revenue / Sales

Pharmaceutical (100.0%)₹ 82.56 Cr

Assets

Pharmaceutical (100.0%)₹ 123.69 Cr

Operating Income

Pharmaceutical (100.0%)₹ 3.34 Cr

Regional Segment Analysis

Brooks Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Brooks Laboratories Ltd.

Historical Segment Analysis

Track how Brooks Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceutical	23	0	0	1

Frequently Asked Questions

What is the revenue of Brooks Laboratories Ltd.?

The latest trailing twelve month revenue of Brooks Laboratories Ltd. is ₹ 85.74 Cr, reflecting a 1-year growth of 3.85% and a 3-year CAGR of 10.70%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Brooks Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Brooks Laboratories Ltd. is ₹ 24.58 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Brooks Laboratories Ltd.?

The operating margin of Brooks Laboratories Ltd. is -. Detailed EBITDA history is available in the Income Statement section of the Statements tab.

What is the EPS of Brooks Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Brooks Laboratories Ltd. is 8.35. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Brooks Laboratories Ltd.?

The debt-to-equity ratio of Brooks Laboratories Ltd. stands at 0.07. The interest coverage ratio is 6.55x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Brooks Laboratories Ltd.?

The estimated book value per share of Brooks Laboratories Ltd. is 41.64 (derived from a P/B ratio of 1.65 and market price of ₹ 68.53), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Brooks Laboratories Ltd.?

The trailing twelve month operating cash flow of Brooks Laboratories Ltd. is ₹ 8.59 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Brooks Laboratories Ltd. report consolidated or standalone financials?

Brooks Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.